Testing Envollizumab and Fruquintinib with SOX vs SOX alone
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study tests whether adding two medicines (Envollizumab and Fruquintinib) to standard chemotherapy (SOX) works better than SOX alone for people with advanced stomach (gastric) cancer that cannot be surgically removed. It aims to improve how long people live and how well the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have stomach adenocarcinoma confirmed by pathology (biopsy or sample)
- Your scans show locally advanced disease that cannot be removed with surgery (no distant spread), and there is at least one measurable tumor on CT
- Your general health is good enough for treatment (ECOG 0–1), and you expect to live more than 3 months
- Your blood counts, liver, and kidney tests are within required ranges
- If you can become pregnant, you have a negative pregnancy test and agree to use birth control; if you are a man, you agree to use contraception or have sterilization
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 2 trial tests whether adding nivolumab to standard chemotherapy (SOX) given before and around surgery can improve outcomes for people with certain stomach or stomach–esophagus junction cancers. It aims to shrink or control the cancer and make surgery more effective.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.